Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Capricor Therapeutics (CAPR)
NASDAQ:CAPR
RESEARCH TOOLSreports
Holding CAPR?
Track your performance easily
Earnings Data
Report Date
Mar 06, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.18Last Year’s EPS
-$0.02Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 13, 2024
|% Change Since: -16.74%
|Next Earnings Date:Mar 06, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted Capricor's strategic progress towards FDA approval and market expansion for deramiocel, bolstered by strong financial positioning and positive payer feedback. However, challenges like revenue decline and increased net loss were noted. Despite these challenges, the advancements and positive outlook position the company favorably for future growth.Company Guidance
In the third quarter 2024 earnings call for Capricor Therapeutics, the company outlined several key metrics and future plans. Capricor is preparing to file a Biologics License Application (BLA) for their product deramiocel, aimed at treating cardiomyopathy associated with Duchenne Muscular Dystrophy (DMD), with expectations to hear from the FDA by the first quarter of 2025 and potential approval by the second half of 2025. The company raised approximately $86 million through a public offering, bringing their cash reserves to $165 million, providing a financial runway into 2027. Capricor also anticipates capturing 50% to 60% of the U.S. DMD population, or roughly 8,000 patients, if deramiocel is approved, with the expectation of transitioning 100 patients initially from open-label extensions to commercial use. Additionally, Capricor highlighted ongoing manufacturing scale-up efforts and a collaboration with Nippon Shinyaku, which could lead to $1.5 billion in milestone payments for European market distribution rights.Filing for Full FDA Approval
Capricor is filing a BLA for full FDA approval for deramiocel to treat cardiomyopathy associated with DMD, with a potential PDUFA date in the second half of 2025.
Strong Financial Position
Capricor raised approximately $86 million in an oversubscribed public offering, resulting in a cash position of approximately $165 million, providing a runway into 2027.
Potential Expansion into European Market
Capricor entered into a term sheet with Nippon Shinyaku for the marketing, sales, and distribution of deramiocel in Europe, potentially leading to milestone payments totaling $1.5 billion.
Manufacturing Capabilities
Capricor has a fully operational manufacturing facility in San Diego and plans to expand manufacturing to meet anticipated demand.
Positive Feedback from Payers
Initial discussions with payers have been very positive, with reimbursement expected to be consistent with other DMD therapies.
---
CAPR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CAPR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 13, 2024 | $16.91 | $18.49 | +9.34% |
| Aug 07, 2024 | $3.56 | $3.88 | +8.99% |
| May 13, 2024 | $5.44 | $5.20 | -4.41% |
| Feb 29, 2024 | $4.20 | $4.56 | +8.57% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Capricor Therapeutics (CAPR) report earnings?
Capricor Therapeutics (CAPR) is schdueled to report earning on Mar 06, 2025, TBA Not Confirmed.
What is Capricor Therapeutics (CAPR) earnings time?
Capricor Therapeutics (CAPR) earnings time is at Mar 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CAPR EPS forecast?
CAPR EPS forecast for the fiscal quarter 2024 (Q4) is -$0.18.
---